South Korea’s Daewoong Pharmaceutical reported record Nabota sales in the first half of the year. The product earned 115.4 billion won, which marks a 28 percent jump from last year. As a result, Daewoong now expects to exceed 200 billion won in total annual Nabota sales.
The company maintains a premium strategy that focuses on high purity, strong safety, and strict quality control. Furthermore, Nabota became the first Asian botulinum toxin approved by the US FDA. It is sold as Jeuveau in the United States, the world’s biggest market for aesthetic toxins.
In fact, Nabota holds a 14 percent share of the US aesthetics segment, ranking second overall. This strong presence highlights Daewoong’s success in the world’s most competitive toxin market. Additionally, the company uses scientific evidence to support its performance claims.
Meanwhile, Daewoong continues to expand its global footprint beyond the US. It has signed major deals in Latin America and Southeast Asia, including markets like Brazil and Thailand. These regions show increasing demand for non-surgical aesthetic procedures.
Recently, Daewoong signed a new agreement with Kuwait, further strengthening its position in the Middle East. Consequently, Nabota now reaches five countries in the region—Kuwait, UAE, Saudi Arabia, Qatar, and another undisclosed market. This marks the broadest Middle East coverage among Korean toxin brands.
Moreover, Daewoong promotes its proprietary injection method, called Nabolift. The company offers global training programs to educate medical professionals on this technique. These sessions improve patient outcomes while increasing global brand recognition.
With growing Nabota sales, Daewoong aims to solidify its leadership in the aesthetics sector. It focuses on innovation, clinical excellence, and strategic market entry. Likewise, the company continues to build long-term trust with doctors and clinics.
Additionally, Daewoong expects future growth from both developed and emerging markets. Global trends support demand for high-quality, non-invasive cosmetic treatments. Nabota stands well-positioned to meet this rising demand with premium performance.
By expanding distribution, offering training, and targeting key regions, Daewoong boosts Nabota’s global brand status. As sales continue rising, South Korea strengthens its influence in the global pharmaceutical and aesthetics industries.
